NCT04641871 2024-06-26
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
Symphogen A/S
Heinrich-Heine University, Duesseldorf
University of Chicago
Abramson Cancer Center at Penn Medicine